These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series. De Sousa-Amorim E; Revuelta I; Diekmann F; Cofan F; Lozano M; Cid J; Palou E; Sole M; Campistol JM; Oppenheimer F Nephrology (Carlton); 2016 Aug; 21(8):700-4. PubMed ID: 26492594 [TBL] [Abstract][Full Text] [Related]
23. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts. Cooper JE; Gralla J; Chan L; Wiseman AC Clin Transpl; 2011; ():359-64. PubMed ID: 22755431 [TBL] [Abstract][Full Text] [Related]
25. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen. Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671 [TBL] [Abstract][Full Text] [Related]
26. Association of Kidney Graft Loss With De Novo Produced Donor-Specific and Non-Donor-Specific HLA Antibodies Detected by Single Antigen Testing. Süsal C; Wettstein D; Döhler B; Morath C; Ruhenstroth A; Scherer S; Tran TH; Gombos P; Schemmer P; Wagner E; Fehr T; Živčić-Ćosić S; Balen S; Weimer R; Slavcev A; Bösmüller C; Norman DJ; Zeier M; Opelz G; Transplantation; 2015 Sep; 99(9):1976-80. PubMed ID: 25769065 [TBL] [Abstract][Full Text] [Related]
27. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients. Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R Clin Transpl; 2014; ():215-21. PubMed ID: 26281148 [TBL] [Abstract][Full Text] [Related]
29. Expression patterns of B cells in acute kidney transplant rejection. Carpio VN; Noronha Ide L; Martins HL; Jobim LF; Gil BC; Külzer AS; Loreto Mda S; Gonçalves LF; Manfro RC; Veronese FV Exp Clin Transplant; 2014 Oct; 12(5):405-14. PubMed ID: 25299368 [TBL] [Abstract][Full Text] [Related]
30. Prospective Monitoring of Donor-specific Anti-HLA Antibodies After Intestine/Multivisceral Transplantation: Significance of De Novo Antibodies. Kubal C; Mangus R; Saxena R; Lobashevsky A; Higgins N; Fridell J; Tector AJ Transplantation; 2015 Aug; 99(8):e49-56. PubMed ID: 25769071 [TBL] [Abstract][Full Text] [Related]
31. Clinicopathologic characteristics and outcomes of late acute antibody-mediated rejection in Thai kidney transplant recipients: a single-center experience. Larpparisuth N; Premasathian N; Vareesangthip K; Cheunsuchon B; Parichatikanon P; Vongwiwatana A Transplant Proc; 2014; 46(2):477-80. PubMed ID: 24655993 [TBL] [Abstract][Full Text] [Related]
32. Efficacy of bortezomib for reducing donor-specific antibodies in children and adolescents on a steroid minimization regimen. Nguyen S; Gallay B; Butani L Pediatr Transplant; 2014 Aug; 18(5):463-8. PubMed ID: 24814755 [TBL] [Abstract][Full Text] [Related]
33. Bortezomib for the treatment of de novo HLA antibody-related antibody mediated rejection. Al Meshari K Clin Transpl; 2009; ():385-6. PubMed ID: 20524302 [No Abstract] [Full Text] [Related]
34. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation. Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814 [TBL] [Abstract][Full Text] [Related]
35. Deleterious Impact of Donor-Specific Anti-HLA Antibodies Toward HLA-Cw and HLA-DP in Kidney Transplantation. Bachelet T; Martinez C; Del Bello A; Couzi L; Kejji S; Guidicelli G; Lepreux S; Visentin J; Congy-Jolivet N; Rostaing L; Taupin JL; Kamar N; Merville P Transplantation; 2016 Jan; 100(1):159-66. PubMed ID: 26262501 [TBL] [Abstract][Full Text] [Related]
36. Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation. Kim MG; Kim YJ; Kwon HY; Park HC; Koo TY; Jeong JC; Jeon HJ; Han M; Ahn C; Yang J Nephrology (Carlton); 2013 Dec; 18(12):820-6. PubMed ID: 24033843 [TBL] [Abstract][Full Text] [Related]
37. Changes in IgG subclasses of donor specific anti-HLA antibodies following bortezomib-based therapy for antibody mediated rejection. Kannabhiran D; Everly MJ; Walker-McDermott JK; Tiongko S; Friedlander R; Putheti P; Sharma V; Dadhania D Clin Transpl; 2012; ():229-35. PubMed ID: 23721027 [TBL] [Abstract][Full Text] [Related]
38. Prognostic Value of the Persistence of C1q-Binding Anti-HLA Antibodies in Acute Antibody-Mediated Rejection in Kidney Transplantation. Bailly E; Anglicheau D; Blancho G; Gatault P; Vuiblet V; Chatelet V; Morelon E; Malvezzi P; Parissiadis A; Tourret J; Guidicelli G; Sayegh J; Mousson C; Grimbert P; Top I; Le Quintrec M; Purgus R; Westeel PF; Proust B; Chabot V; Lebranchu Y; Dehaut F; Büchler M Transplantation; 2018 Apr; 102(4):688-698. PubMed ID: 29135832 [TBL] [Abstract][Full Text] [Related]
39. Four-year allograft survival in a highly sensitized combined liver-kidney transplant patient despite unsuccessful anti-HLA antibody reduction with rituximab, splenectomy, and bortezomib. Koch M; Gräser C; Lehnhardt A; Pollok JM; Kröger N; Verboom M; Thaiss F; Eiermann T; Nashan B Transpl Int; 2013 Aug; 26(8):e64-8. PubMed ID: 23672514 [TBL] [Abstract][Full Text] [Related]
40. Use of bortezomib to treat anti-HLA antibodies in renal transplant patients: a single-center experience. Cicora F; Paz M; Mos F; Roberti J Transpl Immunol; 2013 Dec; 29(1-4):7-10. PubMed ID: 23994721 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]